Kala Bio Inc Reports Results For The Quarter: Earnings Summary

KALA BIO

12/11/2024 15:26

* KALA BIO Inc  KALA.OQ  reported a quarterly adjusted loss
of
$1.93​​ per share for the quarter , higher than the same quarter
last year, when the company reported EPS of $-3.41.  The mean
expectation of two analysts for the quarter was for a loss of
$2.43 per share. Wall Street expected results to range from
$-2.71 to $-2.15 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * KALA BIO Inc's reported EPS for the quarter was a loss of
$1.93​.
    * The company reported a quarterly loss of $8.95 million.
    * KALA BIO Inc shares had risen by 29.8% this quarter and
gained 5.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 31% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "buy."

Wall Street's median 12-month price target for KALA BIO Inc is
$15.00 
This summary was machine generated from LSEG data November 12 at
03:26 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -2.43          -1.93          Beat
 Jun. 30 2024      -4.40          -3.16          Beat
 Mar. 31 2024      -2.89          -4.19          Missed
 Dec. 31 2023      -3.62          -3.18          Beat